JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
134.05 USD
-3.17 (-2.31%)
134.05 USD
0 (0%)
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of JAZZ while its profitability can be described as average. A decent growth rate in combination with a cheap valuation! Better keep an eye on JAZZ.
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
In the past year JAZZ had a positive cash flow from operations.
In multiple years JAZZ reported negative net income over the last 5 years.
JAZZ had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of JAZZ (-3.70%) is better than 74.48% of its industry peers.
Looking at the Return On Equity, with a value of -10.92%, JAZZ is in the better half of the industry, outperforming 72.92% of the companies in the same industry.
The Return On Invested Capital of JAZZ (5.47%) is better than 83.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 15.44%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(5.47%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROIC | 5.47% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 15.03%, JAZZ belongs to the best of the industry, outperforming 85.42% of the companies in the same industry.
JAZZ's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 88.71%, JAZZ belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
JAZZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
JAZZ has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, JAZZ has more shares outstanding
JAZZ has a worse debt/assets ratio than last year.
2.2 Solvency
JAZZ has an Altman-Z score of 1.41. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
JAZZ's Altman-Z score of 1.41 is fine compared to the rest of the industry. JAZZ outperforms 61.46% of its industry peers.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.33, JAZZ belongs to the best of the industry, outperforming 84.90% of the companies in the same industry.
JAZZ has a Debt/Equity ratio of 1.17. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.17, JAZZ is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.41 |
ROIC/WACC0.79
WACC6.91%
2.3 Liquidity
A Current Ratio of 1.62 indicates that JAZZ should not have too much problems paying its short term obligations.
JAZZ's Current ratio of 1.62 is on the low side compared to the rest of the industry. JAZZ is outperformed by 66.15% of its industry peers.
A Quick Ratio of 1.37 indicates that JAZZ should not have too much problems paying its short term obligations.
JAZZ has a worse Quick ratio (1.37) than 64.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
JAZZ shows a small growth in Revenue. In the last year, the Revenue has grown by 6.12%.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)6.12%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
The Earnings Per Share is expected to grow by 6.55% on average over the next years.
The Revenue is expected to grow by 6.20% on average over the next years.
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y6.55%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y6.2%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.43, the valuation of JAZZ can be described as correct.
84.38% of the companies in the same industry are more expensive than JAZZ, based on the Price/Earnings ratio.
JAZZ is valuated rather cheaply when we compare the Price/Earnings ratio to 25.67, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 5.95, the valuation of JAZZ can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 94.27% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of JAZZ to the average of the S&P500 Index (31.86), we can say JAZZ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.43 | ||
| Fwd PE | 5.95 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaply inside the industry as 90.10% of the companies are valued more expensively.
JAZZ's Price/Free Cash Flow ratio is rather cheap when compared to the industry. JAZZ is cheaper than 93.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.56 | ||
| EV/EBITDA | 8.97 |
4.3 Compensation for Growth
JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.01
EPS Next 2Y3.08%
EPS Next 3Y5.52%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
134.05
-3.17 (-2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.51%
Inst Owner Change-0.64%
Ins Owners2.49%
Ins Owner Change0.32%
Market Cap8.13B
Revenue(TTM)4.07B
Net Income(TTM)-404.84M
Analysts84.8
Price Target193.36 (44.24%)
Short Float %7.98%
Short Ratio6.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.5%
Min EPS beat(2)-64.64%
Max EPS beat(2)-6.35%
EPS beat(4)2
Avg EPS beat(4)-10.46%
Min EPS beat(4)-64.64%
Max EPS beat(4)17.85%
EPS beat(8)3
Avg EPS beat(8)-9.87%
EPS beat(12)4
Avg EPS beat(12)-16.71%
EPS beat(16)7
Avg EPS beat(16)-10.46%
Revenue beat(2)0
Avg Revenue beat(2)-6.37%
Min Revenue beat(2)-10.66%
Max Revenue beat(2)-2.09%
Revenue beat(4)1
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.73%
Revenue beat(12)1
Avg Revenue beat(12)-2.38%
Revenue beat(16)3
Avg Revenue beat(16)-2.09%
PT rev (1m)1.53%
PT rev (3m)1.85%
EPS NQ rev (1m)-2.65%
EPS NQ rev (3m)16.14%
EPS NY rev (1m)0.91%
EPS NY rev (3m)11.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.43 | ||
| Fwd PE | 5.95 | ||
| P/S | 1.99 | ||
| P/FCF | 6.56 | ||
| P/OCF | 6.18 | ||
| P/B | 2.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.97 |
EPS(TTM)8.16
EY6.09%
EPS(NY)22.52
Fwd EY16.8%
FCF(TTM)20.44
FCFY15.25%
OCF(TTM)21.69
OCFY16.18%
SpS67.37
BVpS61.1
TBVpS-47.92
PEG (NY)N/A
PEG (5Y)3.01
Graham Number105.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROCE | 6.92% | ||
| ROIC | 5.47% | ||
| ROICexc | 6.73% | ||
| ROICexgc | 82.21% | ||
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% | ||
| FCFM | 30.34% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.37 | ||
| Cap/Depr | 11.29% | ||
| Cap/Sales | 1.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.28% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 1.41 |
F-Score5
WACC6.91%
ROIC/WACC0.79
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y6.55%
Revenue 1Y (TTM)6.12%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y6.2%
EBIT growth 1Y-0.29%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-54.85%
EBIT Next 3Y4.81%
EBIT Next 5Y7.57%
FCF growth 1Y25.59%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y-4.47%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
What is the valuation status of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
How financially healthy is JAZZ PHARMACEUTICALS PLC?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
Can you provide the expected EPS growth for JAZZ stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -74.64% in the next year.